MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
TherapeuticsMD EBITDA 2011-2026 | TXMD
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA TherapeuticsMD
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -7.6 M | 2.38 M | -78.8 M | -154 M | -151 M | -130 M | -77.4 M | -90.1 M | -85.1 M | -54 M | -25.8 M | -16.1 M | -5.37 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.38 M | -154 M | -67.1 M |
Quarterly EBITDA TherapeuticsMD
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -766 K | -599 K | -776 K | - | -1.04 M | -2.61 M | -1.01 M | - | - | -2.34 M | -2.64 M | - | -14.3 M | -14.7 M | -17.5 M | -35.4 M | -36.8 M | -33.1 M | -28.3 M | -34.6 M | -24.7 M | -44.8 M | -49.9 M | - | -26.9 M | -41.5 M | -38 M | - | -34.3 M | -33 M | -24.7 M | - | -14.8 M | -19.8 M | -21.2 M | - | -25.1 M | -21.2 M | -21 M | - | -19.5 M | -27.2 M | -20.9 M | - | -17.8 M | -10.9 M | -8.94 M | - | -7.2 M | -5.61 M | -4.93 M | 28.8 K | -3.9 M | -3.96 M | -2.85 M | - | -1.4 M | -1.02 M | -758 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 28.8 K | -49.9 M | -17.1 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Drug manufacturers industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aerie Pharmaceuticals
AERI
|
-40 M | - | - | $ 754 M |  USA |
 |
AcelRx Pharmaceuticals
ACRX
|
-16.6 M | - | 7.5 % | $ 6.35 M | USA |
 |
Catalent
CTLT
|
-260 M | - | - | $ 11.5 B | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-23.6 M | - | 0.86 % | $ 117 M | USA |
 |
DURECT Corporation
DRRX
|
-36.9 M | - | - | $ 50.1 M | USA |
 |
Endo International plc
ENDP
|
306 M | - | - | $ 28.9 M |  Irlanda |
 |
Agile Therapeutics
AGRX
|
-19.8 M | - | 10.11 % | $ 58.2 M | USA |
 |
Canopy Growth Corporation
CGC
|
-95.6 M | $ 1.1 | 2.84 % | $ 118 M |  Canada |
 |
Evoke Pharma
EVOK
|
-7.43 M | - | - | $ 36.6 M | USA |
 |
Alimera Sciences
ALIM
|
6.82 M | - | - | $ 142 M | USA |
 |
Cronos Group
CRON
|
-176 M | $ 2.64 | 1.35 % | $ 1.38 B | Canada |
 |
Evolus
EOLS
|
-25.2 M | $ 5.68 | 37.53 % | $ 366 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-39.7 M | - | - | $ 2.06 B |  France |
 |
Jupiter Wellness
JUPW
|
429 K | - | - | $ 33.6 M | USA |
 |
China Pharma Holdings
CPHI
|
-1.97 M | $ 0.59 | 6.08 % | $ 10.3 M |  China |
 |
Cumberland Pharmaceuticals
CPIX
|
3.06 M | $ 3.81 | -16.81 % | $ 53.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-524 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-85.5 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Harrow Health
HROW
|
31.8 M | $ 40.02 | 3.65 % | $ 1.47 B | USA |
 |
Neoleukin Therapeutics
NLTX
|
-52.3 M | - | - | $ 193 M | Canada |
 |
Aurora Cannabis
ACB
|
-283 M | $ 3.65 | 4.89 % | $ 86.3 M | Canada |
 |
Athenex
ATNX
|
-65.5 M | - | -23.39 % | $ 1.76 M | USA |
 |
Emergent BioSolutions
EBS
|
-601 M | $ 8.95 | 0.39 % | $ 458 M | USA |
 |
ProPhase Labs
PRPH
|
28.3 M | - | - | $ 5.07 M | USA |
 |
Assertio Holdings
ASRT
|
-215 M | $ 12.19 | 2.48 % | $ 866 M | USA |
 |
Radius Health
RDUS
|
-53.2 M | - | - | $ 1.42 B | USA |
 |
Bausch Health Companies
BHC
|
2.23 B | $ 5.67 | -0.87 % | $ 2.07 B | Canada |
 |
Lannett Company
LCI
|
-142 M | - | 1.15 % | $ 7.11 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
81.6 M | - | -39.89 % | $ 27.7 M | USA |
 |
Organogenesis Holdings
ORGO
|
12.3 M | $ 2.87 | 0.01 % | $ 378 M | USA |
 |
OrganiGram Holdings
OGI
|
-91.8 M | $ 1.4 | 2.19 % | $ 402 M | Canada |
 |
Rockwell Medical
RMTI
|
-5.23 M | $ 0.91 | 1.03 % | $ 21.2 M | USA |
 |
Perrigo Company plc
PRGO
|
-785 M | $ 11.71 | 2.81 % | $ 1.62 B | USA |
 |
Sundial Growers
SNDL
|
-132 M | $ 1.55 | 1.21 % | $ 3.37 M | Canada |
 |
Veru
VERU
|
-36.6 M | $ 2.53 | 0.4 % | $ 341 M | USA |
 |
Viatris
VTRS
|
3.51 B | $ 14.74 | -1.04 % | $ 17.7 B | USA |
 |
Pacira BioSciences
PCRX
|
5.41 M | $ 22.92 | 3.69 % | $ 1.06 B | USA |
 |
PetIQ
PETQ
|
81.6 M | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
-22.3 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
-40.7 M | - | -27.8 % | $ 2.56 M | USA |
 |
Recro Pharma
REPH
|
4.65 M | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
-104 M | $ 4.79 | 2.57 % | $ 144 M | USA |
 |
cbdMD
YCBD
|
-2.86 M | $ 0.75 | -2.76 % | $ 3.23 M | USA |
 |
SCYNEXIS
SCYX
|
73.2 M | $ 0.76 | 1.22 % | $ 36.4 M | USA |
 |
Solid Biosciences
SLDB
|
-127 M | $ 6.14 | 3.02 % | $ 251 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-3.57 M | $ 2.74 | -0.36 % | $ 3.4 M | USA |
 |
Tricida
TCDA
|
-153 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
-1.37 B | $ 7.33 | -0.48 % | $ 4.53 B | Canada |
 |
Zynerba Pharmaceuticals
ZYNE
|
-35 M | - | - | $ 55.5 M | USA |